Cullgen is a privately held biopharmaceutical company with a leading proprietary platform to hijack the cellular ubiquitin-proteasome system for selective removal of disease-causing proteins. We are using our proprietary protein degradation technology platform - uSMITE (ubiquitin-mediated, small molecule- induced target elimination) to develop first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. Typically, drugs are designed to interact with the functional sites of proteins and block their activities. We are developing uSMITE to expand the drug design paradigm beyond functional site inhibition, to make it possible to eliminate previously “undruggable” enzymes and proteins by targeted destruction. Cullgen is initially focusing on the development of protein degrader molecules for the oncology (cancer) market.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):